-
Mashup Score: 10BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition - 4 year(s) ago
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non-small cell lung cancers. Direct KRAS blockade has proven challenging and inhibition of a key downstream effector pathway, the RAF-MEK-ERK cascade, has shown limited success due to activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 14Clinical Development of BRAF plus MEK Inhibitor Combinations - 4 year(s) ago
Genomic profiling shows that many solid tumors are characterized by specific driver aberrations, and this has expanded the therapeutic options for many patients. The mitogen-activated protein kinase (MAPK) pathway is a key cell signaling pathway involved in regulating cellular growth, proliferation, and survival. Driver mutations in the BRAF gene, a key player in the MAPK pathway, are described…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Hot off the press 👉Clinical Development of #BRAF plus #MEK Inhibitor Combinations #melanoma #Anaplastic #thyroidcancer #lungcancer #LCSM #FDA approved indications & beyond @trendscancer @CellPressNews #PrecisionMedicine https://t.co/lM0rKh8t3b https://t.co/KTbzivviP7
-
-
Mashup Score: 7Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer - 4 year(s) ago
In mouse models of KRAS mutant pancreatic ductal adenocarcinoma, tumor cell senescence following MEK and CDK4/6 inhibition promotes vascular remodeling through induction of a pro-angiogenic senescence-associated secretory phenotype, leading to enhanced drug delivery and T cell infiltration that sensitizes these tumors to chemotherapy and immune checkpoint blockade.
Source: CellCategories: General Medicine Journals and SocietiesTweet-
In the latest issue of Cell: #mouse models of #KRAS mutant #pancreatic ductal #adenocarcinoma shows how #tumor cell senescence following #MEK and CDK4/6 inhibition promotes vascular remodeling, leading to enhanced drug delivery + #Tcell infiltration https://t.co/WLQMKhnhNG https://t.co/MGdk69js2Q
-
Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 @Boehringer #DrugDevelopment https://t.co/CN675cexL1 https://t.co/eBbVCNfXJr